8-K: Creative Medical Technology Holdings Issues Inducement Warrants to Encourage Exercise of Existing Warrants

Creative Medical Technology Holdings incentivizes warrant holders to exercise existing warrants through the issuance of new inducement warrants, aiming to raise approximately $3.7 million for working capital.

Summary

• Creative Medical Technology Holdings, Inc. (the Company) entered into warrant exercise inducement offer letters (the Inducement Letters) with the holders (the Holders) of warrants to purchase an aggregate of 837,104 shares of the Company's common stock originally issued on October 23, 2024.
• The Holders agreed to exercise the Existing Warrants at their current exercise price of $4.42 per share, in exchange for the Company's agreement to issue the Holders new warrants to purchase an aggregate of 1,674,208 shares of common stock (the Inducement Warrants).
• The aggregate gross proceeds from the exercise of the Existing Warrants will be approximately $3.7 million, before deducting financial advisory fees.
• The net proceeds received by the Company will be used for working capital and general corporate purposes.
• The Inducement Warrants have an exercise price of $3.75 per share and will be exercisable for a period of five years following the date the Company obtains such stockholder approval.
• Roth Capital Partners, LLC (Roth) acted as the Company's financial advisor in connection with the transactions described above.
• The Company has agreed to (i) pay Roth a financial advisory fee equal to 8% of the aggregate gross proceeds received from the Holders exercise of the Existing Warrants, (ii) reimburse Roth an aggregate of $40,000 for its legal expenses and (iii) issue Roth or its designees warrants to purchase shares of common stock equal to 5.0% of the aggregate number of shares of common stock issuable upon exercise of the Existing Warrants and the Inducement Warrants.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is raising capital, which is generally a positive sign. However, there are costs associated with the inducement offer, and the exercise of the warrants is contingent upon stockholder approval.

Positives

• The company expects to raise approximately $3.7 million in gross proceeds for working capital and general corporate purposes.
• The inducement offer encourages the exercise of existing warrants, potentially increasing the company's cash reserves.
• The shares of common stock issuable upon exercise of the Existing Warrants are registered for issuance pursuant to a registration statement on Form S-1 (File No. 333-283091), which was declared effective by the Securities and Exchange Commission (the SEC) on November 19, 2024.

Negatives

• The company will incur financial advisory fees to Roth Capital Partners, including an 8% fee on gross proceeds, $40,000 for legal expenses, and warrants for 5% of the total shares issuable.
• The Inducement Warrants have not been registered under the Securities Act or applicable state securities laws.

Risks

• The Inducement Warrants and underlying shares are subject to resale restrictions as they have not been registered under the Securities Act.
• The exercise of the Inducement Warrants is contingent upon obtaining stockholder approval.
• The company's ability to utilize the net proceeds effectively for working capital and general corporate purposes is subject to execution risk.

Future Outlook

The company intends to use the net proceeds from the exercise of the existing warrants for working capital and general corporate purposes. The company also plans to file a resale registration statement on Form S-3 with the SEC within thirty days of the closing to register the resale of the shares of common stock issuable upon exercise of the Inducement Warrants.

Industry Context

Companies often use warrant inducement programs to accelerate the exercise of outstanding warrants, providing an immediate influx of capital. This is a common strategy, especially for companies seeking to strengthen their balance sheets or fund growth initiatives.

Comparison to Industry Standards

• Warrant inducement programs are a fairly common practice, but the specific terms, such as the ratio of new warrants to existing warrants and the exercise price, can vary widely.
• The 8% financial advisory fee to Roth Capital Partners is within the typical range for such transactions, although the inclusion of warrants for 5% of the total shares issuable is a significant component of the compensation.
• Comparable companies like BioLineRx and Galmed Pharmaceuticals have used similar strategies to raise capital, but the details of each transaction are tailored to the specific circumstances of the company and its existing warrant structure.

Stakeholder Impact

• Shareholders may experience dilution upon the exercise of the Inducement Warrants.
• The company's financial position is expected to improve with the influx of capital.
• Employees may benefit from the increased working capital and general corporate purposes.

Next Steps

• The company needs to obtain stockholder approval for the issuance of shares underlying the Inducement Warrants.
• The company will file a resale registration statement on Form S-3 with the SEC within thirty days of the closing.
• The company will list the New Warrant Shares on the Nasdaq Capital Market.

Key Dates

Keywords

inducement warrants, warrants, exercise, common stock, capital raise, Roth Capital Partners, shareholder approval, private placement